- Home
- SAFT vs MLYS Comparison
SAFT vs MLYS Comparison
Compare SAFT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAFT
- MLYS
- Stock Information
- Founded
- SAFT 1979
- MLYS 2019
- Country
- SAFT United States
- MLYS United States
- Employees
- SAFT N/A
- MLYS N/A
- Industry
- SAFT Property-Casualty Insurers
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- SAFT Finance
- MLYS Health Care
- Exchange
- SAFT Nasdaq
- MLYS Nasdaq
- Market Cap
- SAFT 1.0B
- MLYS 890.6M
- IPO Year
- SAFT N/A
- MLYS 2023
- Fundamental
- Price
- SAFT $72.58
- MLYS $34.80
- Analyst Decision
- SAFT
- MLYS Strong Buy
- Analyst Count
- SAFT 0
- MLYS 5
- Target Price
- SAFT N/A
- MLYS $33.75
- AVG Volume (30 Days)
- SAFT 98.0K
- MLYS 2.4M
- Earning Date
- SAFT 11-04-2025
- MLYS 08-12-2025
- Dividend Yield
- SAFT 5.04%
- MLYS N/A
- EPS Growth
- SAFT 65.99
- MLYS N/A
- EPS
- SAFT 5.73
- MLYS N/A
- Revenue
- SAFT $1,199,774,000.00
- MLYS N/A
- Revenue This Year
- SAFT N/A
- MLYS N/A
- Revenue Next Year
- SAFT N/A
- MLYS N/A
- P/E Ratio
- SAFT $12.75
- MLYS N/A
- Revenue Growth
- SAFT 16.96
- MLYS N/A
- 52 Week Low
- SAFT $68.76
- MLYS $8.24
- 52 Week High
- SAFT $90.00
- MLYS $35.02
- Technical
- Relative Strength Index (RSI)
- SAFT 46.92
- MLYS 92.12
- Support Level
- SAFT $71.81
- MLYS $14.94
- Resistance Level
- SAFT $74.76
- MLYS $15.79
- Average True Range (ATR)
- SAFT 1.30
- MLYS 2.02
- MACD
- SAFT -0.09
- MLYS 2.24
- Stochastic Oscillator
- SAFT 20.90
- MLYS 98.61
About SAFT Safety Insurance Group Inc.
Safety Insurance Group Inc is a provider of private passenger automobile, commercial automobile, and homeowners insurance in Massachusetts. The company also offers property and casualty insurance products, including commercial automobiles, homeowners, dwelling fire, umbrella, and business owner policies. It operates in the business segment of Property and casualty insurance operations.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.